Chai Discovery

Chai Discovery is building foundation models for drug discovery that predict molecular interactions and enable zero-shot design of therapeutic molecules. Backed by OpenAI, the company's Chai-2 model has demonstrated breakthrough capabilities in predicting how biochemical molecules interact, achieving what the company describes as 100x improvement in zero-shot antibody design. Chai Discovery reached unicorn status with a $1.3 billion valuation in December 2025.

$225M+

Total raised

Foundation models for predicting molecular interactions and designing therapeutic molecules. Chai-2 enables zero-shot antibody design with claimed 100x improvement over prior methods, without requiring target-specific training data.